PURPOSE: To report abnormalities in the @entity7131 pathway and other @entity432 risk factors in @entity1 with @entity732 . METHODS: In a study, we investigated 76 consecutive @entity1 who had in- @entity1 evaluation of @entity455 . All @entity1 underwent comprehensive tests for @entity3459 including determinations of @entity7131 , protein S, @entity4555 , and resistance to activated @entity7131 and were screened for @entity455 risk factors. Resistance to activated @entity7131 was confirmed by a polymerase chain reaction method to detect the specific factor V @entity54821 mutation. For comparative purposes, we also screened 209 consecutive inpatients with @entity1150 from the same geographic region for resistance to activated @entity7131 as well as @entity7131 and @entity4889 . RESULTS: Ten (29%) of 35 @entity1 with central @entity2994 (CRVO) had factor V @entity54821 mutation. The factor V @entity54821 mutation was detected in four (19%) of 21 @entity1 with @entity2994 . The higher frequency in factor V @entity54821 mutation compared with the expected 9% mutation prevalence in a white population was highly significant for the central @entity2994 group but not for the @entity2994 group. In all @entity1 with resistance to activated @entity7131 , the factor V @entity54821 mutation was detected; 16 were heterozygous, one homozygous. No cases of @entity4555 , @entity7131 , or @entity4889 were detected. Forty (19%) of 209 @entity1 with @entity1150 were carriers of the factor V @entity54821 mutation. CONCLUSIONS: The prevalence of the factor V @entity54821 mutation is similar in @entity1 with central @entity2994 and @entity1 with @entity1150 and represents a relevant risk factor. Screening for this mutation is therefore recommended in all @entity1 with central @entity2994 .

@entity732 and deficiencies in the XXXX pathway.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity455 :: ('MESH:D014652', 'Disease') :: ['venous or arterial retinal vascular occlusion', 'vascular disease'] @entity4889 :: ('MESH:D018455', 'Disease') :: ['protein S deficiencies'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['branch retinal vein occlusion', 'retinal vein occlusion'] @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein C'] @entity3459 :: ('MESH:D025861', 'Disease') :: ['coagulation disorders'] @entity54821 :: ('p|SUB|R|506|Q', 'ProteinMutation') :: ['R506Q'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis'] @entity4555 :: ('MESH:C531622', 'Disease') :: ['lupus anticoagulants'] @entity432 :: ('MESH:D001157', 'Disease') :: ['vascular occlusion'] @entity732 :: ('MESH:D015356', 'Disease') :: ['retinal vascular occlusion']
@entity7131 :: (MESH:D020151,Disease) :: ['protein C']
